IL-25/IL-17E Protein, Human (Biotinylated, HEK293, His-Avi)

IL-25/IL-17E cytokine, produced by eosinophils, Th2 cells, and epithelial cells, crucially regulates adaptive immune responses by modulating cytokine production. It enhances T-helper type 2 responses locally and systemically through its IL17RA and IL17RB receptor, activating the JAK2-STAT5A pathway. This activation leads to the secretion of type-2-associated cytokines, including IL4, IL9, and IL13, while inhibiting Th17 cell differentiation. IL-25 also induces IL8 and IL6 release from eosinophils via MAPK and NF-kappa-B pathways, emphasizing its regulatory role in immune responses. IL-25/IL-17E Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived IL-25/IL-17E protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of IL-25/IL-17E Protein, Human (Biotinylated, HEK293, His-Avi) is 145 a.a., with molecular weight of 25-35 kDa.

The cytokine IL-25/IL-17E, produced by various cells such as eosinophils, T-helper type 2 (Th2) cells, or epithelial cells, plays a crucial role in the internal safety of adaptive immune responses by regulating cytokine production. This cytokine promotes and augments T-helper type 2 responses both locally and systemically, acting through its receptor composed of IL17RA and IL17RB for signal transduction. Upon binding, IL-25 activates the JAK2-STAT5A pathway, leading to the secretion of type-2-associated cytokines, including IL4, IL9, and IL13. Additionally, it induces the release of IL8 and IL6 from eosinophils by simultaneously activating the MAPK and NF-kappa-B pathways. Notably, IL-25 inhibits the differentiation of T-helper (Th17) cells through the production of IL4, IL5, and IL13, contributing to its regulatory role in immune responses.

Human

HEK293

C-Avi;C-His

Q9H293-1 (Y33-G177)

64806  [NCBI]

25-35 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.